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Introduction {#sec1}
============

Histaminergic neurons in the tuberomammilary nucleus (TMN), a region of the posterior hypothalamus, help sustain wakefulness ([@bib5; @bib17; @bib29; @bib30; @bib32; @bib34; @bib37; @bib38; @bib44; @bib65; @bib71]). They are the sole source of neuronal histamine and send axons throughout the brain ([@bib9; @bib35; @bib66]). TMN neurons become active just after waking and fire at an average rate of about 5 Hz, and their activity is suppressed during sleep ([@bib43; @bib44; @bib53]). Histamine modulates diverse circuitries ([@bib15; @bib17; @bib65]). Histamine can suppress, for example, glutamate or GABA inputs to local circuits by activating hetero-H3 metabotropic receptors on terminals; it can also depolarize cells via H1 and H2 metabotropic receptors or cause phosphorylation of ion channels that influence firing rate ([@bib8; @bib15]). These effects can occur in the same local circuitry. At the behavioral level, the net effects of histamine's actions on circuits are enhanced aspects of wakefulness such as cognition, locomotion, feeding, and motivation ([@bib56]).

Physiological investigations have focused on the histaminergic aspect of TMN neurons. But these neurons also contain glutamic acid decarboxylase (GAD) enzymes and GABA itself ([@bib3; @bib47; @bib54; @bib59; @bib63]). GABA's presence in histaminergic neurons is conserved, from fish through to humans, suggesting a core function ([@bib51; @bib59]). It is not known what this function is, and there has been no demonstration that these cells actually release GABA. Optogenetic stimulation of histaminergic fibers in the ventral lateral preoptic (VLPO) area of the hypothalamus found that histamine release stimulated local GABAergic interneurons ([@bib67]), but provided no evidence of GABA release from the histamine fibers.

Varicosities on TMN axons broadcast histamine by volume transmission---histaminergic neurons rarely use synapses ([@bib52]). So it is likely that if these same TMN axons do release GABA, then this particular source of GABA would also function, similar to histamine, in a paracrine manner that would principally affect extrasynaptic receptors. Because GABA is an electroneutral *zwitterion* at physiological pH, it has diminished interactions with the extracellular matrix. Thus GABA is well suited for diffusion over long distances ([@bib41]). Ambient (nonsynaptic) GABA produces sustained inhibitory currents by activating high-affinity extrasynaptic ionotropic GABA~A~ receptors ([@bib12; @bib11; @bib28]); this is termed the tonic inhibitory conductance (*G*~*tonic*~).

In this paper we start by showing that selective pharmacogenetic stimulation of histamine neurons enhances behavioral arousal. We then demonstrate that knocking down or removing *vgat* gene expression from histaminergic neurons increases locomotion, and causes a substantial increase in wakefulness during the night. Optogenetically stimulating histaminergic fibers in the neocortex and caudate-putamen increases *G*~*tonic*~ onto pyramidal neurons and medium spiny cells, respectively. Eliminating *vgat* from histaminergic neurons selectively abolishes these evoked tonic inhibitory currents. Thus, during wakefulness, GABA can be deposited widely in neocortical and striatal circuitry by volume transmission. The GABA and histamine TMN components work together to regulate the amount of wakefulness.

Results {#sec2}
=======

Histaminergic Neurons Stimulate Arousal but Are Also GABAergic {#sec2.1}
--------------------------------------------------------------

We first tested the excitatory nature of histaminergic neurons on behavior by selectively stimulating them pharmacogenetically in vivo with DREADD hM3Dq-mCherry receptors and clozapine-N-oxide (CNO) ([@bib4; @bib26]). The *hM3Dq* receptor is an excitatory metabotropic receptor. Histaminergic neurons can be genetically targeted because of their unique expression of the histidine decarboxylase (*hdc*) gene, allowing the generation of *HDC-Cre* mice ([@bib71; @bib72]). The TMN area of *HDC-Cre* mice was bilaterally transduced with *AAV-flex-hM3Dq-mCherry* ([Figure 1](#fig1){ref-type="fig"}A) to produce *HDC-hM3Dq* mice. Intraperitoneal administration of CNO, but not saline, to these *HDC-hM3Dq* mice significantly increased their motor activity in an open area ([Figure 1](#fig1){ref-type="fig"}B) (saline, n = 4; CNO, n = 4, two-way ANOVA and post hoc Bonferroni, ^∗^p \< 0.05; ^∗∗^p \< 0.01; measurements taken 30 min post CNO or saline injection). In these mice, the *hM3Dq-mCherry* receptor was selectively expressed in most histaminergic neurons (348 mCherry-positive cells out of 405 HDC-positive cells were counted across three animals; 85% ± 3.5% of the HDC-neurons were mCherry positive) ([Figure 1](#fig1){ref-type="fig"}C). Using whole-cell recording in acute slices from the TMN area of *HDC-hM3Dq* mice (n = 4 mice), we demonstrated that CNO significantly (paired t test, p \< 0.05) depolarized TMN neurons by ∼5 mV (n = 11 cells, control, −46 ± 3 mV; CNO, −41 ± 2 mV). This was sufficient to elicit action potential (AP) firing in silent cells (5 out of 11) or increase AP firing rate in spontaneously active cells ([Figure 1](#fig1){ref-type="fig"}D). Thus, selectively activating histaminergic neurons generated hyperlocomotion and behavioral arousal.

In spite of this excitatory effect on behavior, histaminergic TMN cells contain GABA and its synthetic enzyme GAD67 (*gad1*) ([@bib3; @bib54; @bib63]). By immunocytochemistry, we found that a majority of HDC-positive neurons costained strongly with GAD67 antisera (1,399 GAD67-positive cells out of 1,720 HDC-positive cells were counted across three animals; 81% ± 10% of the HDC neurons were GAD67 positive; [Figure 2](#fig2){ref-type="fig"}A). We corroborated this result genetically by crossing *HDC-Cre* mice with conditional *rosa-lox-stop-lox-YFP* mice ([@bib49]). In these crosses, 85% ± 5% (n = 3 mice) of YFP-positive neurons in the TMN also expressed GAD67 ([Figure 2](#fig2){ref-type="fig"}B). Conventionally, if histaminergic neurons were to release GABA, they should also express the vesicular GABA transporter (*vgat*, *Slc32a1*) gene. With the exception of midbrain dopamine neurons ([@bib57; @bib58]), vGAT has so far proved essential for all neurons that release GABA ([@bib55; @bib70]); *vgat* expression, however, has not been demonstrated for HDC cells. Crossing *vGAT-Cre* mice ([@bib64]) with those containing a *rosa-lox-stop-lox-tdTomato* allele ([@bib31]) gave extensive tdTomato/HDC soma costaining in the TMN ([Figure 2](#fig2){ref-type="fig"}C). Thus histaminergic neurons express the *vgat* gene and have the potential to package GABA into vesicles.

Genetic Disruption of GABA Function in Histaminergic Neurons {#sec2.2}
------------------------------------------------------------

To remove the putative GABAergic function from histaminergic neurons, we considered crossing either *vgat*^*lox/lox*^ mice or double *gad1*^*lox/lox*^*/gad2*^*lox/lox*^ mice with the *HDC-Cre* mice. However, the *hdc-cre*, *vgat*, *gad1*, and *gad2* genes are all in the same region of mouse chromosome 2, which precluded easy generation of homozygous *HDC-Cre/vgat*^*lox/lox*^ or *HDC-Cre/gad1*^*lox/lox*^*/gad2*^*lox/lox*^ animals. We therefore developed *vgat*-selective shRNA constructs to knock down *vgat* expression ([Figure 3](#fig3){ref-type="fig"} and see [Figure S1](#mmc1){ref-type="supplementary-material"} available online). For this we placed putative *vgat* shRNA sequences into a microRNA gene, *mir30*, in the 3′ untranslated region of a transcript that also encodes dsRed ([@bib50]). These constructs were termed *dsRed-shvgat* (oligo1, oligo2, or oligo3) ([Figure 3](#fig3){ref-type="fig"}A). We tested how well these constructs could reduce *vgat* reporter gene expression in transfected HEK293 cells by cotransfecting *dsRed-shvgat* (oligo1, oligo2, or oligo3) with *CMV-vGAT*, respectively. Two shRNAs strongly knocked down *vgat* reporter gene expression in HEK cells ([Figures 3](#fig3){ref-type="fig"}B and 3C, p \< 0.05, t test). Before moving to the more challenging area of the TMN, we used a striatum-based motor assay to demonstrate that the constructs, delivered in AAVs, worked effectively in vivo ([Figure S1](#mmc1){ref-type="supplementary-material"}). To compare the behavior produced by knockdown and knockout of vGAT in the caudate-putamen (CPu), we unilaterally injected *AAV-dsRed-shvgat* and *AAV-Cre-2A-Venus* into wild-type and *vgat*^*lox/lox*^ mice, respectively, to generate *CPu-vgat KD* and *CPu-Δvgat* mice ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1D). Both *CPu-vgat KD* and *CPu-Δvgat* groups had significantly decreased *vgat* transcript levels ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1E) and increased ipsilateral turning compared with controls ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1F).

To knock down *vgat* expression selectively in histaminergic neurons, we placed the dsRed-shvgat and dsRed-scramble cassettes in reverse orientation between heterologous lox sites (a FLEX switch) ([Figure 3](#fig3){ref-type="fig"}D), so that expression could only be induced by CRE recombinase ([@bib7]). The *AAV-flex-dsRed-shvgat* or *AAV-flex-dsRed-scramble* viruses were bilaterally injected into the TMN area of HDC-Cre mice ([Figure 3](#fig3){ref-type="fig"}D). The groups of mice are referred to as *HDC-vgat KD* and *HDC-scramble*, respectively. We also injected AAV-Cre-2A-Venus and *AAV-GFP* into the TMN area of *vgat*^*lox/lox*^ mice to produce *TMN-Δvgat* and *TMN-GFP* mice, respectively ([Figure 3](#fig3){ref-type="fig"}F). In *TMN-Δvgat* mice, the injections covered the TMN area; 77% ± 2% of HDC-positive neurons expressed Cre-2A-Venus ([Figure S2](#mmc1){ref-type="supplementary-material"}). In the TMN, all of the GAD67-positive neurons also contained HDC ([Figure 2](#fig2){ref-type="fig"}A). These *TMN-Δvgat* mice formed an approximate comparison for the *HDC-vgat KD* mice, with the caveat that some GABAergic cells in the TMN area in addition to the histaminergic cells could be affected. We tested the vgat gene expression levels in the TMN area of *HDC-vgat KD* and *TMN-Δvgat* mice by both qPCR on tissue punches and also single-cell qPCR from identified neurons in acute brain slices prepared from the TMN area ([Figure S3](#mmc1){ref-type="supplementary-material"}). The tissue-punch analysis showed that in both *TMN-Δvgat* and *HDC-vgat KD* mice, vgat mRNA levels in the TMN were significantly decreased compared with those in *TMN-GFP* or *HDC-scramble* mice (*TMN-GFP*, 1 ± 0.06 versus *TMN-Δvgat*, 0.5 ± 0.06, t test, ^∗∗^p \< 0.01; *HDC-scramble*, 1 ± 0.04 versus *HDC-vgat KD*, 0.76 ± 0.05, t test, ^∗^p \< 0.05) ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). The single-cell qPCR showed that in both *TMN-Δvgat* and *HDC-vgat KD* mice, the vgat mRNA levels from identified single neurons were also significantly decreased compared with those in *TMN-GFP* or *HDC-scramble* mice (*TMN-GFP*, 1 ± 0.46 versus *TMN-Δvgat*, 0.06 ± 0.02, t test, ^∗^p \< 0.05; *HDC-scramble*, 1 ± 0.24 versus *HDC-vgat KD*, 0.35 ± 0.17, t test, ^∗^p \< 0.05) ([Figures S3](#mmc1){ref-type="supplementary-material"}D--S3G). The content of histamine in the neocortex and caudate-putamen of *HDC-vgat KD* and *TMN-Δvgat* mice was unchanged (see [Figure S4](#mmc1){ref-type="supplementary-material"}).

*HDC-vgat KD* and *TMN-Δvgat* Mice Are Hyperactive {#sec2.3}
--------------------------------------------------

We first quantified the general activity of the mice. In an open field assay, *HDC-vgat KD* mice ran significantly further and had higher instantaneous speeds than the *HDC-scramble* controls, maintaining a stable and high activity for the 30 min duration of the test ([Figure 3](#fig3){ref-type="fig"}E; *HDC-scramble*, n = 7; *HDC-vgat KD*, n = 8, two-way ANOVA and post hoc Bonferroni, ^∗^p \< 0.05; ^∗∗^p \< 0.01). Similarly, the *TMN-Δvgat* mice were continuously more active compared with *TMN-GFP* control mice ([Figure 3](#fig3){ref-type="fig"}G; *TMN-GFP*, n = 10; *TMN-Δvgat*, n = 6, two-way ANOVA and post hoc Bonferroni, ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001). In fact, the activity of the *TMN-Δvgat* mice, as measured by instantaneous speed and distance covered, tended to increase toward the end of the experiment ([Figure 3](#fig3){ref-type="fig"}G).

*HDC-vgat KD* and *TMN-Δvgat* Mice Have Increased and Sustained Wakefulness during the Night {#sec2.4}
--------------------------------------------------------------------------------------------

We used EEG/EMG analysis to assess the sleep-wake cycle ([Figures 4](#fig4){ref-type="fig"} and [S5](#mmc1){ref-type="supplementary-material"}A). The *HDC-vgat KD* and *TMN-Δvgat* mice exhibited similar changes in their sleep-wake behavior, largely confined to the night. First we describe the *HDC-vgat KD* (n = 6) and *HDC-scramble* (n = 6) groups ([Figures 4](#fig4){ref-type="fig"}A--4C and [S5](#mmc1){ref-type="supplementary-material"}B). For the first half of the night, *HDC-vgat KD* mice had significantly more wake than the *HDC-scramble* controls ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S5](#mmc1){ref-type="supplementary-material"}B) (wake, *HDC-scramble*, 400 ± 13 min versus *HDC-vgat KD*, 511 ± 15 min, t test, ^∗∗∗^p \< 0.001). The example in [Figure 4](#fig4){ref-type="fig"}A shows the EEG from an *HDC-vgat KD* mouse that was awake continuously for 6 hr during the first half of the night. In fact, during the night, *HDC-vgat KD* mice had only about 65% of normal NREM sleep compared with HDC-scramble mice (NREM, *HDC-scramble*, 293 ± 12 min versus *HDC-vgat KD*, 190 ± 14 min, t test, ^∗∗∗^p \< 0.001). Their REM sleep was also slightly decreased (*HDC-scramble*, 22 ± 2 min versus *HDC-vgat KD*, 17 ± 2 min, t test, ^∗^p \< 0.05). The EEG θ power of *HDC-vgat KD* mice was significantly increased selectively during the night ([Figure 4](#fig4){ref-type="fig"}C) (two-way ANOVA and post hoc Bonferroni, ^∗∗∗^p \< 0.001), consistent with the heightened wakefulness of *HDC-vgat KD* mice ([Figure 4](#fig4){ref-type="fig"}B). In the day, both the *HDC-vgat KD* and *HDC-scramble* mice showed a similar sleep-wake pattern---with the same amount of NREM sleep and wake ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S5](#mmc1){ref-type="supplementary-material"}B; wake, *HDC-scramble* (n = 6), 243 ± 10 min versus *HDC-vgat KD* (n = 6), 252 ± 18 min, t test, p \> 0.05; NREM, *HDC-scramble* (n = 6), 425 ± 10 min versus *HDC-vgat KD* (n = 6), 409 ± 12 min, t test, p \> 0.05).

Similar to *HDC-vgat KD* mice, *TMN-Δvgat* mice had a strong "sustained wakefulness" phenotype confined to the night ([Figures 4](#fig4){ref-type="fig"}D, 4E, and [S5](#mmc1){ref-type="supplementary-material"}C). Compared with the *TMN-GFP* controls (n = 5), *TMN-Δvgat* (n = 7) animals were awake nearly the whole night (*TMN-GFP*, 411 ± 9 min versus *TMN-Δvgat*, 586 ± 27 min, t test, ^∗∗∗^p \< 0.001). Conversely, these *TMN-Δvgat* mice exhibited little NREM sleep during the dark period ([Figures 4](#fig4){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}C; *TMN-GFP*, 258 ± 12 min versus *TMN-Δvgat*, 118 ± 25 min, t test, ^∗∗^p \< 0.01). Their amount of REM sleep was also decreased (*TMN-GFP*, 48 ± 9 min versus *TMN-Δvgat*, 13 ± 3 min, t test, ^∗∗^p \< 0.01). Similar to the *HDC-vgat KD* mice, selectively during the night, *TMN-Δvgat* mice had a strong increase of their maximum θ power frequency ([Figure 4](#fig4){ref-type="fig"}F). Thus both the *HDC-vgat KD* and *TMN-Δvgat* mice slept less. Their loss of sleep during the dark phase was not balanced by a corresponding increase in sleep duration during the day (two-way ANOVA and post hoc Bonferroni, ^∗∗∗^p \< 0.001).

After Sleep Deprivation, *HDC-vgat KD* and *TMN-Δvgat* Mice Still Sleep Less Than Control Mice, Maintaining Their Hyperactive State {#sec2.5}
-----------------------------------------------------------------------------------------------------------------------------------

Given the lack of sleep displayed by the *HDC-vgat KD* and *TMN-Δvgat* mice during a typical 24 hr cycle, we investigated how they behaved after sleep deprivation. Compared with control mice, would they demonstrate more recovery sleep to compensate for general lack of sleep during the normal sleep-wake cycle? Mice were sleep deprived for 5 hr during the beginning of the day by presenting them with novel objects. After sleep deprivation, mice were allowed recovery sleep in their home cages ([Figure S6](#mmc1){ref-type="supplementary-material"}). Compared with the control mice, *HDC-vgat KD* mice had less NREM recovery sleep ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B), but the rate at which they reaccumulated their lost NREM sleep (∼12.5 extra minutes NREM sleep recovered/hour) was similar to controls ([Figure S6](#mmc1){ref-type="supplementary-material"}C). *TMN-Δvgat* mice behaved more extremely ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). After sleep deprivation they were awake longer than control sleep-deprived mice and some 16 hr after sleep deprivation were spending most of their time awake ([Figure S6](#mmc1){ref-type="supplementary-material"}E). However, as for the *TMN-Δvgat* mice, the rate at which they reaccumulated their lost NREM sleep (∼12 extra minutes NREM sleep recovered/hour) was similar to controls ([Figure S6](#mmc1){ref-type="supplementary-material"}F). Thus *HDC-vgat KD* and *TMN-Δvgat* mice sleep less than control mice, maintaining their hyperactive state even after sleep deprivation.

Histaminergic Axons in Neocortex and Striatum Release Paracrine GABA {#sec2.6}
--------------------------------------------------------------------

Histamine neurons can globally coordinate behavioral states because their axons spread and diverge throughout the brain ([@bib36; @bib52; @bib65]). Can the axonal projections of histaminergic neurons release GABA, and does this release require vGAT? The behavioral results with *HDC-vgat KD* and *TMN-Δvgat* mice imply that this is the case. We addressed this directly using optogenetic stimulation in two types of mice: *HDC-Channel-Rhodopsin*(*ChR*) mice and *TMN-Δvgat/HDC-ChR* mice. To make *HDC-ChR* mice, the TMN area of *HDC-Cre* mice was bilaterally injected with *AAV-flex-ChR2H134R-EYFP* ([Figures 5](#fig5){ref-type="fig"}A and 5B). A TMN acute slice from *HDC-ChR* mice with ChR-EYFP primary fluorescence is shown in [Figure 5](#fig5){ref-type="fig"}B. The ChR-EYFP fusion protein was enriched in the membrane of HDC-neurons, including their axons ([Figures 5](#fig5){ref-type="fig"}B and 5C). Brief 1 ms stimuli were delivered to the LED every 200 ms, resulting in a 460 nm 0.1 mW/mm^2^ peak light pulse that decayed with a time course of 10 msec. A continuous 5 Hz protocol was delivered for 3 min to HDC-ChR-EYFP-positive neurons in acute TMN slices ([Figure 5](#fig5){ref-type="fig"}D). This ChR stimulation protocol was capable of entraining action potential firing at 5 Hz ([Figure 5](#fig5){ref-type="fig"}E), corresponding to wake-active firing rates of TMN neurons ([@bib53]). The ChR-EYFP fusion protein is an excellent substrate for anterograde axonal transport ([@bib39; @bib60]). EYFP-positive fibers, marking the presence of ChR, were present in both the caudate-putamen ([Figures 5](#fig5){ref-type="fig"}F and 5G) and all neocortical areas examined e.g., sensory, motor, and visual neocortex ([Figures 5](#fig5){ref-type="fig"}H and 5I). The *TMN-Δvgat/HDC-ChR* mice have light-sensitive HDC neurons with deleted *vgat* gene expression. To make these, we coinjected *AAV-Cre-2A-Venus* and *AAV-flex-ChR2-EYFP* bilaterally into the TMN area of *vgat*^*lox/lox*^ mice ([Figures 6](#fig6){ref-type="fig"}A and 6B).

We carried out functional circuit mapping by light-stimulating the ChR-EYFP labeled fibers in the neocortex ([Figure 6](#fig6){ref-type="fig"}C) and caudate-putamen ([Figure 6](#fig6){ref-type="fig"}J) prepared from *TMN-Δvgat/HDC-ChR* and *HDC-ChR* mice. Stimulation of *HDC-ChR* neocortical slices with brief light pulses delivered at 5 Hz generated slow and sustained increases in the holding current recorded, in whole-cell mode, from pyramidal cells ([Figure 6](#fig6){ref-type="fig"}D). This current resembled the *G*~*tonic*~ produced by activation of extrasynaptic GABA~A~ receptors ([@bib12; @bib11; @bib13; @bib68]). On average, G~*tonic*~ significantly increased by 1.1 ± 0.3 nS (paired t test, p \< 0.01; n = 8) in the *HDC-ChR* slices ([Figure 6](#fig6){ref-type="fig"}E). In the example shown ([Figure 6](#fig6){ref-type="fig"}D), the enhancement of G~*tonic*~ was apparent after a few minutes of 5 Hz continuous optical stimulation, consistent with GABA diffusing to its target receptors from distant release sites (i.e., a paracrine action). To determine whether the GABA was being released directly from HDC terminals or if this required an interneuron intermediate, we repeated these experiments in the presence of TTX (1 μM) and 4-AP (100 μM) ([@bib42]). A robust increase in G~*tonic*~ was observed, and on average it significantly increased by 0.5 ± 0.1 nS (paired t test, p \< 0.01; n = 9) in the HDC-ChR slices ([Figure 6](#fig6){ref-type="fig"}F). In contrast, there was no increase in *G*~*tonic*~ in *TMN-Δvgat/HDC-ChR* slices following 5 Hz light stimulation ([Figure 6](#fig6){ref-type="fig"}G). On average G~*tonic*~ was slightly reduced by −0.2 ± 0.1 nS (n = 9) in the *TMN-Δvgat/HDC-ChR* mice (paired t test, p = 0.225, n = 9; [Figure 6](#fig6){ref-type="fig"}H). This suggests that vesicular GABA was being directly released from the histaminergic fibers using GABAergic (vGAT-dependent) vesicles to cause the increase in G~*tonic*~. The results also imply that the *G*~*tonic*~ is not caused by activating any putative histamine-gated chloride channels ([@bib16]).

We next confirmed, independently of the HDC-specific *vgat* knockouts, that histamine release was not responsible for stimulating GABAergic interneurons to release GABA. We repeated the 5 Hz light stimulation of *HDC-ChR* fibers in the presence of the H1 receptor antagonist pyrilamine (20 μM) and the H2 receptor antagonist ranitidine (5 μM). A significant increase in G~*tonic*~ (0.6 ± 0.2 nS, n = 11; paired t test, p \< 0.05) still occurred ([Figure 6](#fig6){ref-type="fig"}I), and as before, the increase was delayed after the onset of light stimulation. Applying H1/H2 receptor antagonists further suggested that there was no intermediary GABAergic interneuron involved that first required excitation by histamine, and which then released GABA to increase *G*~*tonic*~. Instead, GABA release in the neocortex from TMN axons was vGAT dependent.

ChR-EYFP-positive fibers were also present in the caudate putamen of *HDC-ChR* mice ([Figure 6](#fig6){ref-type="fig"}J). During 5 Hz light stimulation, there was a gradual increase in G~*tonic*~ (1.9 ± 0.6 nS, n = 7; paired t test, p \< 0.05) onto medium spiny neurons ([Figure 6](#fig6){ref-type="fig"}K). When the GABA~A~ receptor antagonist gabazine (100 μM) was present during the stimulation, there was no increase in G~*tonic*~; in fact, on average it decreased by −0.8 ± 0.5 nS (n = 6) ([Figure 6](#fig6){ref-type="fig"}L).

GABA Released from Histaminergic Axons Does Not Increase Phasic Inhibition, but Histamine Increases Synaptic Drive {#sec2.7}
------------------------------------------------------------------------------------------------------------------

We examined if GABA release from "GABA-histaminergic" axons in neocortex of *HDC-ChR* mice increased phasic (synaptic) GABA~A~ receptor activation, in addition to its ability to raise G~*tonic*~. The timing of sPSCs was analyzed relative to the LED trigger ([Figure 7](#fig7){ref-type="fig"}A). By cross-correlation analysis, sPSCs were not phase locked with ChR stimulation ([Figure 7](#fig7){ref-type="fig"}B) (n = 9 recordings from four *HDC-ChR* mice). However, the sPSC frequency significantly increased in these neocortical slices from 6.4 ± 1.7 Hz (n = 9) to 9.5 ± 2.2 Hz (paired t test, p \< 0.05). This increase in asynchronous sPSC frequency was not observed when these experiments were repeated in the presence of TTX/4-AP ([Figure 7](#fig7){ref-type="fig"}C), although G~*tonic*~ did significantly increase (see [Figure 6](#fig6){ref-type="fig"}F). A similar increase in sPSC frequency was observed in the *TMN-Δvgat/HDC-ChR* mice, where the sPSC frequency increased from 8.7 ± 2.8 Hz (n = 9) to 15.6 ± 3.3 Hz (paired t test, p \< 0.05). However, in these mice there was no increase in G~*tonic*~ (see [Figure 6](#fig6){ref-type="fig"}H). Does this light-evoked increase in sPSC rate depend on histamine release? In the presence of the H1 receptor antagonist pyrilamine (20 μM) and the H2 receptor antagonist ranitidine (5 μM), the ChR-stimulated increase in the rate of asynchronous sPSCs was blocked at the start and at the end of stimulation ([Figure 7](#fig7){ref-type="fig"}D; 23.9 ± 6.0 Hz \[start\] to 21.9 ± 5.4 Hz \[end\]; n = 11, paired t test, p = 0.3). For neocortical layer neurons, these data highlight the independent nature of the two signals from histaminergic-GABA axons originating from the TMN: an increased synaptic drive generated by histamine release and an increased G~*tonic*~ generated by GABA release.

Discussion {#sec3}
==========

Histamine neurons form a globally projecting hub that integrates brain functions associated with wakefulness ([@bib65]). Starting in the TMN, histaminergic axons course large distances throughout the brain, generating extrasynaptic pools of transmitter. We showed that selective pharmacogenetic stimulation of these histamine neurons in vivo behaviorally excites the animals, as would be expected ([@bib17; @bib29; @bib32; @bib34]). But we also established that histaminergic neurons use vGAT to release GABA. Similar to histamine, the GABA released from histaminergic neurons functions in a paracrine manner, which would make these neurons an unexpected source of GABAergic volume transmission in the neocortex and striatum. As part of their integrative role in specifying behavioral state, we expect that these hypothalamic TMN "GABA-histamine" neurons will contribute to tonic inhibition of many neural circuits simultaneously. Mice whose GABA-histamine neurons cannot release GABA are hyperactive, and they sleep less and do not catch up on this lost sleep. The "sleepless phenotype" manifests during the night. Their behavior might be described as a form of mania ([@bib23]), which in humans would be considered as part of a bipolar disorder.

Neurons often corelease small molecules and peptides ([@bib2; @bib24; @bib45; @bib55; @bib62]). "Orexinergic" neurons, for example, in the lateral hypothalamus corelease glutamate and orexin onto histaminergic neurons in the TMN ([@bib46]). The different time course of the excitatory actions of the two transmitters (glutamate, fast synaptic excitation; orexin, slow and sustained excitation) allows them to signal different aspects of "metabolic integration" ([@bib46]). In addition to peptides, some neurons release several small molecule transmitters simultaneously, sometimes of the same functional type, e.g., GABA-glycine ([@bib22]), but often of functionally antagonist pairings, for example, GABA-glutamate, or GABA-acetylcholine or GABA-dopamine ([@bib20; @bib61]). In contrast to our findings on GABA-histamine neurons, other investigations into GABA cotransmission or corelease, including cotransmission with peptides, found only fast monosynaptic responses generated by the GABA component ([@bib21; @bib42; @bib48; @bib55; @bib57]). It might be expected that midbrain dopamine and histamine networks function similarly with respect to GABA release, but they do not. GABA is not synthesized in the dopamine neurons themselves---unlike the histamine neurons, they do not express the *gad1* or *gad2* genes---but GABA is instead scavenged into dopaminergic terminals by the transporters mGAT1 and mGAT4; it is hypothesized that GABA is then transported into dopamine vesicles by the monoamine transporter VMAT2 ([@bib57; @bib58]). For histamine neurons, *vgat* knockout removes GABA release; the VMAT2 in histamine neurons does not substitute for vGAT. In cultured TMN neurons from embryos, GABA is in putative vesicles distinct from histaminergic ones, suggesting cotransmission rather than corelease ([@bib27]).

There is an intriguing potential for synergy directly at the receptor level between histamine and GABA. At (high) concentrations of around 1 mM, histamine is an effective positive allosteric modulator of α4 subunit-containing GABA~A~ receptors ([@bib10]), which are the type of GABA~A~ receptors often associated with extrasynaptic activation ([@bib11]). However, when we removed *vgat* from histamine (HDC-ChR) axons, this abolished the light-evoked increase in tonic inhibition on layer IV pyramidal neurons, suggesting that the histamine released was not sufficient to activate any α4 subunit-containing GABA~A~ receptors that might have been present. Similarly, the *vgat* deletion experiment also ruled out that the increase in *G*~*tonic*~ was due to activating (speculative) histamine-gated chloride channels ([@bib16]). In the absence of vGAT, light triggered a general increase in synaptic drive onto pyramidal neurons, which was blocked by H1 and H2 receptor antagonists. This effect of histamine is likely to reflect the engagement of multiple changes in the inputs impinging onto pyramidal neurons, as described for striatal neurons ([@bib15]). As the histamine system innervates most of the brain, further studies will be required to see if GABA is coreleased in other areas. In the ventral lateral preoptic hypothalamus, histamine axons do not release GABA when stimulated optogentically, but instead activate GABA interneurons by histamine release ([@bib67]). By contrast, our experiments using TTX in the neocortex suggest that in this brain region no intermediary interneurons convey TMN axon-evoked GABA release. About 20% of histamine neurons in the TMN only contain histamine ([Figure 2](#fig2){ref-type="fig"}A), and these could be the ones that innervate VLPO.

The "GABA-histamine" TMN neurons only fire during wakefulness, so GABA will be released from their axons into the neocortex and striatum during the wake state. The paracrine nature of the GABA signal explains the lack of any phasic synaptic inhibition associated with GABA release from the histamine axons. Why would GABA-histamine neurons use contradictory "stop-go" signals? One reason could be to stop networks getting too excited by histamine: the *HDC-vgat KD* and *TMN-Δvgat* mice are more active and sleep less because the histaminergic system is overactive. The function of sleep is unknown, but an overactive histamine system, resulting in less sleep, may damage health and cause mania. GABA release from histamine neurons could keep the animal in the "optimal arousal zone."

A second reason could be related to the fact that in the awake neocortex, inhibition enhances processing ([@bib18]). Indeed, the wake-active GABAergic volume transmission generated by TMN neurons may sharpen cognitive responses, and so GABA could work together with histamine to enhance wakefulness. Increased ambient GABA levels will generate greater *G*~*tonic*~, which by speeding up the membrane time constant will increase the requirement for EPSP-spike precision, and constrain coincidence detection so that only closely timed inputs trigger action potentials ([@bib11; @bib13; @bib14; @bib19; @bib69]). The long distances traversed by the GABA-histamine axons mean that extrasynaptic inhibition could be coordinated by the TMN over large cortical areas.

In conclusion, we think it is no longer correct to refer to TMN neurons as "histaminergic": the GABA arm of their activity is so striking that they might be referred to as "GABA-histamine" neurons. We have demonstrated that the wide-ranging GABA-histamine axons of the hypothalamic TMN broadcast dual inhibitory-excitatory signals in the neocortex: an increased G~*tonic*~ generated by GABA release, and an increased synaptic drive generated by histamine. The two components may work together to regulate the amount of wakefulness. If this balance of GABA-histamine cotransmission changes unfavorably, mania-like behaviors could emerge.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

All experiments were performed in accordance with the UK Home Office Animal Procedures Act (1986); all procedures were approved by the Imperial College Ethical Review Committee. The following strains of mice were used: *HDC-Cre* (129SVJ and C57BL/6J) ([@bib72]) (JAX stock number 021198); *Rosa26-loxP-Stop-loxP-YFP* (C57BL/6J), kindly provided by F. Costantini ([@bib49]); *vgat*^*lox/lox*^ (C57BL/6J and 129S4), kindly provided by B.B. Lowell ([@bib55]) (Jax stock number 012897); *vGAT-Cre*, kindly provided by B.B. Lowell ([@bib64]); and *Rosa26-loxP-Stop-loxP-tdTomato*, kindly provided by H. Zeng ([@bib31]). See [Supplemental Information](#app2){ref-type="sec"} for genotyping.

AAV Transgene Plasmids {#sec4.2}
----------------------

Plasmid *pAAV-iCre-2A-Venus* was provided by Thomas Kuner ([@bib1]). Plasmid *pAAV-GFP* was a gift from John T. Gray (Addgene plasmid 32396). Plasmid *pAAV-EF1α-flex-ChR2H134R-EYFP* was a gift from Karl Deisseroth (Addgene plasmid 20298). The H134R mutation enhances light-evoked ChR currents and reduces spike-frequency adaptation ([@bib33; @bib40]). Plasmid *pAAV-hSyn-flex-hM3Dq-mCherry* was a gift from Bryan L. Roth (Addgene plasmid 44361) ([@bib26]). The *pPRIME* system, cloned into AAV transgenes, was used to generate shRNAs in vivo ([@bib50]). See [Supplemental Information](#app2){ref-type="sec"} for shRNA sequences.

Adeno-Associated Virus Preparation and Stereotaxic Injections {#sec4.3}
-------------------------------------------------------------

To produce adeno-associated virus (AAV), the adenovirus helper plasmid *pFΔ6*, the AAV helper plasmids *pH21* (AAV1) and *pRVI* (AAV2), and the *pAAV* transgene plasmids were cotransfected into HEK293 cells and the subsequent AAV particles harvested on heparin columns, as described previously ([@bib25]). To deliver the AAV into the brain, stereotaxic injections were performed using an Angle Two apparatus (Leica) linked to a digital brain atlas (Leica Biosystems Richmond, Inc.). Before injection, 1 μl AAV virus was mixed with 1 μl 20% mannitol (MERCK K93152782 111). The virus and mannitol mixture were injected into a pulled-glass pipette (Warner Instruments; OD = 1.00 mm, ID = 0.78 mm, length = 7.5 cm). Virus was injected at a speed of 25 nl/min. Virus (1 μl) was bilaterally injected into the brain, 0.5 μl for each side. For TMN, the injection coordinates were as follows: ML (−0.92 mm), AP (−2.70 mm), DV (−5.34 mm); ML (0.92 mm), AP (−2.70 mm), and DV (−5.34 mm). For unilateral injections, the injection coordinates were as follows: CPu, ML (−2.10 mm), AP (0.50 mm), and DV (−3.66 mm).

Histamine Measurements {#sec4.4}
----------------------

Neocortex or striatum was collected and homogenized with 10 μl of 0.2 M perchloric acid per mg tissue and centrifuged at 10,000 rpm for 5 min at 4°C. The supernatants were collected and neutralized with an equal volume of 1 M potassium borate buffer. Brain histamine levels were determined with an ELISA kit (Beckman Coulter Co. number IM2562).

qPCR on Tissue Punches and Single-Cell qPCR {#sec4.5}
-------------------------------------------

Total RNA from tissue punches was extracted using Trizol (Invitrogen). Reverse transcription and PCR were performed using a TaqMan RNA-to-Ct 1-Step Kit (Life Technologies, 4392653) and an Applied Biosystems machine (Foster City, USA). Acute slices of the TMN area were made (see "Electrophysiology"). AAV-transduced neurons were identified by fluorescence. After patching and recording (see "Electrophysiology"), we used the Single-Cell-to-CT Kit (Ambion). The content of the neuron was aspirated into the recording pipette and expelled into cell lysis/DNase I solution. Reverse transcription and cDNA preamplification were performed according to the kit protocol. qPCR was performed using the TaqMan Gene Expression Assay system. The TaqMan assay probes were designed and purchased from Invitrogen (UK): *mvgat*, Mm00494138_m1; *m18srRNA*, Mm03928990_g1; and *mhdc*, Mm00456104_m1.

EEG Analysis and Sleep-Wake Behavior {#sec4.6}
------------------------------------

EEG and EMG signals were recorded using Neurologger 2A devices ([@bib6; @bib71]). The sleep state (wake, W; non-rapid eye movement, NREM; rapid eye movement, REM; doubt, D) was scored manually. See [Supplemental Information](#app2){ref-type="sec"} for details. The sleep deprivation procedure, with presentation of novel objects, was performed as described ([@bib71]).

General Behavioral Activity: Open Field Assay {#sec4.7}
---------------------------------------------

All experiments were performed during "lights off" (active phase). The locomotion activity was detected in an activity test chamber with infrared sensors (Med Associates, Inc). The "instantaneous speed" was calculated as the distance traveled divided by the time spent moving (but not including the time the mice spent in the stationary state). For the DREADD experiments, clozapine-N-oxide (C0832, Sigma-Aldrich, dissolved in saline, 5 mg/kg) or saline was administered i.p. 30 min before the start of the behavioral observations.

Electrophysiology {#sec4.8}
-----------------

Acute brain slices were prepared as described in [Supplemental Information](#app2){ref-type="sec"}. For optogenetic experiments, a 470 nm collimated LED (M470L3-C1, Thorlabs) was used to illuminate the slice through the objective lens, and current-clamp recordings were first made from histaminergic neurons to confirm ChR2 expression. Subsequent voltage-clamp experiments in neocortex and stratum were used for cross-correlation analysis of synaptic events using a 100 ms sliding window before and after each LED pulse. Changes in the tonic GABA~A~ receptor-meditated conductance (G~*tonic*~) were calculated from the average holding current.

Supplemental Information {#app2}
========================
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![Pharmacogenetic Activation of Histaminergic Neurons Increased Motor Activity of *HDC-hM3Dq* Mice\
(A) *AAV-flex-hM3Dq-mCherry* was bilaterally injected into the TMN region of *HDC-Cre* mice to give hM3Dq-mCherry expression selectively within histaminergic neurons (see inset image).\
(B) Activity of *HDC-hM3Dq* mice in an open field arena 30 min after saline (black trace, n = 4 mice) or CNO (red trace, n = 4 mice) injection. The distance moved was calculated every 5 min and average values (mean ± SEM) plotted over 60 min (^∗^p \< 0.05; ^∗∗^p \< 0.01).\
(C) Double-label immunocytochemisty of HDC- and hM3Dq-mCherry-positive neurons with HDC antisera and mCherry antibody; arrowheads indicate examples of double-labeled neurons. DAPI labeling was included to locate all cells.\
(D) Two examples of voltage traces recorded from *HDC-hM3Dq* mice during the application of CNO. The top trace shows an example of a silent neuron that was sufficiently depolarized to fire APs. The bottom trace shows a spontaneously active neuron with increased AP firing in the presence of CNO. On average there was a significant (paired t test, p \< 0.05) ∼5 mV depolarization of TMN neurons (n = 11 cells, control, −46 ± 3 mV; CNO, −41 ± 2 mV). The results from each cell are shown on the scatterplot on the right.](gr1){#fig1}

![The Majority of Histaminergic Neurons Express GABAergic Markers\
(A) Coronal section of the mouse posterior hypothalamus stained with HDC (green) and GAD67 (red) antisera. The diagram summarizes the staining from the whole TMN region: HDC-positive cells (green) and double-positive cells (orange). 3V, third ventricle; VTM, ventral tuberomammillary; DTM, diffuse tuberomammillary.\
(B) *HDC-Cre* mice were crossed with *Rosa26-loxP-stop-loxP-YFP* mice to generate *HDC-YFP* mice. TMN sections from *HDC-YFP* mice were costained with EYFP and GAD67 antisera. Most YFP-positive (HDC neurons) in the TMN were also GAD67-positive.\
(C) *vGAT-Cre* mice were crossed with *Rosa26-loxP-stop-loxP-tdTomato* mice to generate *vGAT-tdTomato* mice. Sections from *vGAT-tdTomato* mice were stained with HDC antisera. Most HDC neurons were tdTomato positive.](gr2){#fig2}

![Knocking Down and Knocking Out *vgat* Expression from Histaminergic Neurons in the TMN\
(A) Three hairpin (*sh*) oligonucleotides (*sholigo*), targeting the *vgat* transcript, were designed. Each *sholigo* was separately cloned into the *pPRIME-dsRed* vector; a scramble shRNA was also cloned into *pPRIME-dsRed*.\
(B) To test the knockdown efficiency of the three *shvgat* oligonucleotides in vitro, *CMV-dsRed-scramble* or *CMV-dsRed-shvgat* (1, 2, or 3) were cotransfected with *pCMV-vGAT-3′UTR* (a cDNA containing the vgat open reading frame and 3′ untranslated region) into HEK293 cells. Thirty-six hours later, cells were fixed and stained with vGAT antisera. vGAT expression was best reduced with *sholigo1* and *sholigo3*.\
(C) Three independent transfections were performed, and relative vGAT immunofluorescence in HEK cells was quantified.\
(D) *AAV-flex-dsRed-shvgat (oligo3)* was bilaterally injected into the TMN region of *HDC-Cre* mice. Cre recombination produced *dsRed-shvgat* expression in HDC-positive neurons, and the resulting mice were termed *HDC-vgat KD* mice. Arrowheads indicate examples of colabeled cells.\
(E) *HDC-vgat KD* mice were more active than *HDC-scramble* (*AAV-flex-dsRed-scramble*-injected *HDC-Cre*) mice in an open field assay (^∗^p \< 0.05; ^∗∗^p \< 0.01).\
(F) *AAV-Cre-2A-Venus* was bilaterally injected into the TMN region of *vgat*^*lox/lox*^ mice to generate *TMN-Δvgat* mice. Sections from virus-injected (*TMN-Δvgat*) mice were costained with HDC and GFP (Venus) antisera. In the TMN region, GFP expression was in 77% ± 2% of HDC neurons. Arrowheads indicate examples of colabeled cells.\
(G) *TMN-Δvgat* mice ran further than *TMN-GFP* (*AAV*-*GFP*-injected *vgat*^*lox/lox*^) mice in an open field assay (^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001). During each running episode *TMN-Δvgat* mice also ran faster, as evidenced by instantaneous speed measurements (^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001).](gr3){#fig3}

![GABA Release from Histaminergic Neurons Governs the Amount of Sleep\
(A) Continuous EMG, EEG, delta power, wake, NREM sleep, and REM sleep scoring data recorded for an *HDC-scramble* and an *HDC-vgat KD* mouse for 24 hr.\
(B) The graphs illustrate the average 24 hr sleep scoring (percentage of wake, NREM, or REM sleep) for *HDC-scramble* (black trace) and *HDC-vgat KD* (red trace) mice; bars, SEM.\
(C) Comparison of the power spectra of wake obtained from EEG data recorded during the day and night for the *HDC-scramble* (black trace) and *HDC-vgat KD* (red trace) mice.\
(D) Continuous EMG, EEG, delta power, wake, NREM sleep, and REM sleep scoring data recorded from *TMN-GFP* and *TMN-Δvgat* mice.\
(E) The graphs illustrate the average 24 hr sleep scoring (percentage of wake, NREM, or REM sleep) for *TMN-GFP* (black trace) and *TMN-Δvgat* (red trace) mice; bars, SEM.\
(F) Comparison of the power spectra of wake obtained from EEG data recorded during the day and night for the *TMN-GFP* (black trace) and *TMN-Δvgat* (red trace) mice.](gr4){#fig4}

![Selective ChR2-EYFP Expression in Histaminergic Neurons and Tracing Their Axons to Neocortex and Striatum\
(A) *AAV-flex-ChR2-EYFP* was bilaterally injected into the TMN region of *HDC-Cre* mice. The blue circle indicates the area of the slice that was optically stimulated.\
(B) Cre recombination produced *ChR2-EYFP* expression within HDC-expressing neurons. Shown is a combined bright-field and primary fluorescence photograph, taken at low magnification, of a freshly cut coronal brain slice used for electrophysiological recording from TMN neurons.\
(C) *ChR-EYFP* expression in the TMN imaged with antisera to GFP (green) and HDC (red), with arrowheads indicating ChR2 expression in processes.\
(D) The duration of the LED power output (blue trace) measured from the objective lens, and the membrane voltage recorded (black trace) from the soma of a *HDC-ChR2-EYFP* neuron. Increasing the LED power depolarized the membrane to generate action potentials. Inset image: four neurons recorded from this slice with cofluorescence for *ChR-EYFP* (green) and postrecording neurobiotin fill (red).\
(E) The same cell as (D) firing action potentials with 5 Hz light stimulation.\
(F) Schematic of the fibers (axons) which, following *AAV-flex-ChR2-EYFP* injection into the TMN of *HDC-Cre* mice, transported *ChR-EYFP* from the *HDC-ChR2-EYFP* soma into the neocortex and caudate-putamen.\
(G and H) Low-power photographs of the *ChR2-EYFP*-positive fibers in the caudate-putamen (CPu) (G) and sensory and visual cortex (H). Blue, DAPI; I, layer I; II, layer II; III, layer III; IV, layer IV; V, layer V; VI, layer VI; WM, white matter.\
(I) Schematic of the *ChR2-EYFP* fiber distribution in the caudate-putamen (CPu) and neocortex.](gr5){#fig5}

![Histaminergic Axons Produce Slow GABAergic Responses in Visual Cortex Pyramidal and Striatal Neurons\
(A) Double injection of *AAV-Cre-Venus* and *AAV-flex-ChR2-EYFP* into the TMN of *vgat*^*lox/lox*^ mice to make light-sensitive histaminergic neurons that lack vGAT (*HDC-ChR TMN-Δvgat* mouse).\
(B) The top photomicrograph shows combined expression of the two AAV transgenes in the bilateral TMN area (coronal section). The lower picture shows double staining in the TMN with HDC and EGFP antisera.\
(C) Two layer IV pyramidal neurons filled with neurobiotin/Alexa 555 (red) postrecording.\
(D) Electrophysiological data from a *HDC-ChR* mouse. The gray symbols superimposed upon the current trace (black line) show the average holding current calculated for every 1 s epoch during the entire recording. An increase in the holding current begins during the 5 Hz optogenetic stimulation but takes minutes to reach its peak response following termination of the stimuli.\
(E) Scatterplot for all recordings made from the *HDC-ChR* mice. The lines indicate paired recordings made before and after the 5 Hz optogenetic stimulation. On average, G~*tonic*~ significantly increased by 1.1 ± 0.3 nS (paired t test, p \< 0.01; n = 8) in the *HDC-ChR* slices.\
(F) Scatterplot for all recordings made from the HDC-ChR mice in the presence of TTX and 4-AP. On average, G~tonic~ significantly increased by 0.5 ± 0.1 nS (paired t test, p \< 0.005; n = 9) in the HDC-ChR slices.\
(G) Electrophysiological data from a *HDC-ChR TMN-Δvgat* mouse. The gray symbols superimposed upon the current trace (black line) show the average holding current calculated every 1 s epoch for the entire recording. No change in the holding current occurred in response to the 5 Hz optogenetic stimulation, but there was an increase in the frequency of spontaneous synaptic activity (transient downward deflections).\
(H) Scatterplots for recordings made from the *HDC-ChR TMN-Δvgat* mice. The lines indicate the paired recordings made before and after the 5 Hz optogenetic stimulation. G~*tonic*~ was reduced by −0.2 ± 0.1 nS in the *TMN-Δvgat/HDC-ChR* mice (paired t test, p = 0.225, n = 9).\
(I) Scatterplots for recordings made from the *HDC-ChR* mice in the presence of H1 (pyrilamine) and H2 (ranitidine) blockers. G~*tonic*~ increased by 0.6 ± 0.2 nS (paired t test, p \< 0.05; n = 11).\
(J) Medium spiny neuron (red, neurobiotin fill postrecording) from the caudate-putamen of a *HDC-ChR* mouse; several *ChR-EYFP*-positive axons (green) are in the vicinity of the cell.\
(K and L) Scatterplots for all recordings made from medium spiny neurons in the *HDC-ChR* mice in control conditions and with the GABA~A~ receptor antagonist gabazine (10 μM). G~*tonic*~ increased by 1.9 ± 0.6 nS (paired t test, p \< 0.05; n = 7) in control conditions and decreased by −0.8 ± 0.5 nS in the presence of gabazine (paired t test, p = 0.3; n = 6).](gr6){#fig6}

![Activated Neocortical "GABA-Histamine" Axons Increase Synaptic Drive and *G*~*tonic*~ by Independent Mechanisms\
(A) Whole-cell voltage-clamp recording from a pyramidal cell in layer IV of visual cortex during 5 Hz LED stimulation of axon fibers from an *HDC-ChR* mouse. The left-hand trace is from the start, and the right-hand trace is at the end of, the 5 Hz LED stimuli. The increased holding current between the first and last trace was used to calculate the increase in tonic conductance (ΔG~*tonic*~).\
(B) Cross-correlation analyses between the LED trigger and the occurrence of sPSCs. There was no peak in the histogram, consistent with a lack of LED-triggered PSCs.\
(C) Whole-cell voltage-clamp recording in a layer IV pyramidal cell in the presence of TTX and 4-AP during 5-Hz LED stimulation of axon fibers in the visual neocortex from an *HDC-ChR* mouse. There was an increase in *G*~*tonic*~ but in this experiment little change in sPSC rate.\
(D) Scatterplot of the change in synaptic drive (Hz) onto layer IV visual cortex pyramidal cells for the four main experiments: stimulation of *HDC-ChR* axons, stimulation of *HDC-ChR* axons in the presence of TTX/4-AP, stimulation of *HDC-ChR* axons in the presence of H1 and H2 receptor antagonists, and stimulation of *TMN-Δvgat/HDC-ChR* axons. In *HDC-ChR* mice the sPSC frequency significantly increased from 6.4 ± 1.7 Hz (n = 9) to 9.5 ± 2.2 Hz (paired t test, p \< 0.05). In *TMN-Δvgat/HDC* mice, a similar increase in sPSC frequency was observed from 8.7 ± 2.8 Hz (n = 9) to 15.6 ± 3.3 Hz (paired t test, p \< 0.05). With the H1 receptor antagonist pyrilamine (20 μM) and the H2 receptor antagonist ranitidine (5 μM), the ChR-stimulated increase in the rate of asynchronous sPSCs was 23.9 ± 6.0 Hz at the start and 21.9 ± 5.4 Hz at the end of stimulation (n = 11, paired t test, p = 0.3).](gr7){#fig7}
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